Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ascendis Pharma A/S - Ordinary Share
(NQ:
ASND
)
250.44
+1.46 (+0.58%)
Delayed Quote
Updated: 11:14 AM EST, Nov 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ascendis Pharma A/S - Ordinary Share
< Previous
1
2
3
4
5
6
7
8
9
Next >
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
↗
September 16, 2024
Via
Benzinga
Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year
↗
September 16, 2024
Ascendis Pharma reports positive topline data from the Phase 3 ApproaCH trial of TransCon CNP in children with achondroplasia.
Via
Benzinga
Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug
↗
September 16, 2024
The companies could soon face off in the growth treatment market for children with a genetic disorder.
Via
Investor's Business Daily
Alcoa, Lattice Semiconductor, Stratasys And Other Big Stocks Moving Higher On Monday
↗
September 16, 2024
Via
Benzinga
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
↗
September 04, 2024
Ascendis Pharma reported disappointing Q2 sales of $38.76 million, missing the consensus of $92.7 million. Key updates included a higher-than-expected U.S. price for Yorvipath and a delayed cash flow...
Via
Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $5,900 Today
↗
August 09, 2024
Via
Benzinga
$1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today
↗
July 18, 2024
Via
Benzinga
Here's How Much $1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
↗
July 03, 2024
Via
Benzinga
Why Ascendis Pharma Stock Tumbled by 11% Today
↗
September 04, 2024
A bottom-line whiff and reduced guidance made the company an outlier for the wrong reasons on Hump Day.
Via
The Motley Fool
Ascendis Pharma Slashes Its Outlook Amid Pricing Fiasco, Sacrifices A Breakout
↗
September 04, 2024
Shares are poised to undercut their 50-day and 200-day lines, and the lower boundary of a base.
Via
Investor's Business Daily
Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut
↗
September 04, 2024
Ascendis Pharma reported lower-than-expected Q2 2024 sales of $38.76 million, missing the consensus estimate of $92.7 million due to a significant adjustment to prior sales estimates. The company...
Via
Benzinga
Core & Main Reports Downbeat Results, Joins Rev Group, PagerDuty, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
↗
September 04, 2024
Via
Benzinga
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
September 03, 2024
Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes
From
Royalty Pharma plc
Via
GlobeNewswire
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Years
↗
June 26, 2024
Via
Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have $4,100 Today
↗
May 31, 2024
Via
Benzinga
Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday
↗
August 13, 2024
Via
Benzinga
Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues
↗
August 12, 2024
FDA grants approval to Ascendis Pharma's Yorvipath (TransCon PTH) for adult hypoparathyroidism. Yorvipath offers continuous parathyroid hormone exposure and is set to launch in the U.S. with patient...
Via
Benzinga
Ascendis Pharma Zips Higher After FDA Approves Embattled Thyroid Drug
↗
August 12, 2024
The company faced a number of regulatory setbacks that pushed its initial expected approval date out from April.
Via
Investor's Business Daily
Macy's, Ascendis Pharma And 3 Stocks To Watch Heading Into Friday
↗
July 05, 2024
U.S. stock futures rise, Macy's receives higher offer, LGI Homes sells 571 homes, Telefonaktiebolaget records impairment charge, GFL declares dividend.
Via
Benzinga
(ASND) - Analyzing Ascendis Pharma's Short Interest
↗
May 28, 2024
Via
Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $6,500 Today
↗
May 17, 2024
Via
Benzinga
$100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today
↗
May 06, 2024
Via
Benzinga
FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months
↗
May 15, 2024
Ascendis Pharma announces FDA's extension of the review date for TransCon PTH for adults with hypoparathyroidism to August 14, 2024. TransCon PTH aims to address low calcium levels due to...
Via
Benzinga
Masters In Trading - Saturday, May 11
↗
May 11, 2024
In this recap of the most recent trading session, I discuss earnings results and the market rally seen throughout the past week.
Via
Talk Markets
ASND Stock Earnings: Ascendis Pharma Reported Results for Q1 2024
↗
May 02, 2024
Ascendis Pharma just reported results for the first quarter of 2024.
Via
InvestorPlace
Looking Into Ascendis Pharma's Recent Short Interest
↗
April 26, 2024
Via
Benzinga
$1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today
↗
April 18, 2024
Via
Benzinga
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
↗
April 06, 2024
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates...
Via
Talk Markets
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
↗
April 03, 2024
Via
Benzinga
Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
↗
March 14, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
